secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-016130
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q2 net loss $90.6M; BEACON Phase 3 RVO study meets endpoint
---------------------------------------------------------------------------

- Net loss of $90.6M ($1.74/share) vs $55.9M ($1.08/share) in Q2 2021 driven by higher R&D and stock-based comp.
- Cash and equivalents $597.9M at quarter-end, down from prior quarter but sufficient for operations.
- BEACON study in RVO met primary endpoint: tarcocimab every 8 weeks non-inferior to aflibercept monthly.
- Phase 3 DME studies GLEAM/GLIMMER and wet AMD study DAYLIGHT fully enrolled; topline data expected mid-2023.
- Plans to file single BLA for tarcocimab across all indications if Phase 3 data are positive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022016130/0000950170-22-016130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022016130/kod-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer